Overview

• The phase 1 trial enrolled 12 patients with end-stage metastatic colorectal cancer, utilizing CRISPR/Cas9 to edit tumor-infiltrating lymphocytes (TILs).
• Knocking out the intracellular checkpoint gene CISH enhanced T cell recognition and attack on tumors, a novel approach inaccessible to traditional therapies.
• The gene-edited TIL infusions were well tolerated, with no serious adverse events linked to the gene-editing procedure.
• Several patients experienced disease stabilization, and one achieved a complete response, with metastatic tumors disappearing and not recurring for over two years.
• Efforts are now focused on reducing production costs, simplifying manufacturing processes, and expanding clinical evaluations to validate and optimize the therapy.